Abstract: Objective To compare the efficacy and adverse events of TAC and TP regimens as neoadjuvant chemotherapy for triple negative breast carcinoma（TNBC）. Methods One hundred and two cases of TNBC patients with pathological diagnose were divided into TAC group（52 cases） and TP group（50 cases）. TAC group：docetaxel 75mg／m² or taxol 135mg／m² iv d₁，ADM 40mg／m² or epirubicin 75mg／m² iv d₂，CTX 600mg／m² iv d₁；TP group： docetaxel 75mg／m² or taxol 135mg／m² iv d₁，cisplatin 30mg／m² iv d₂-d₄. All patients were operated after neoadjuvant chemotherapy for 2-4 cycles at a interval of 21 days. The efficacy and adverse reaction were evaluated. Results In TAC group， 5 cases gained pathological complete response，35 cases gained partial response，9 cases was stable. In TP group， 4 cases gained pathological complete response， 32 cases gained partial response， 5 cases was stable. There was no significant difference in the pathological complete response rate between two groups（P=0.774）， and the overall response rate（RR） was with no significant difference too（P=0.568）. There were 12 cases with progressive disease after chemotherapy for 2 cycles, 3 cases in TAC group and 9 cases in TP group. There were 2 cases with atrial extrasystoles in TAC group, 3 cases with impairment of kidney in TP group. 3-4 degree toxicity of hematologic rate and alopecia rate in TAC group were higher than those of TP group； but 3-4 degree incidence rate of gastrointestinal reaction in TP group were higher than that in TAC group. There were significant statistical differences（P=0.000）.Conclusion TAC and TP regimens for triple negative breast cancer patients is effective and well tolerated.